AstraZeneca wins first FDA approval for systemic lupus drug in a decade biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
By Reynald Castaneda 12 May 2021 (Last Updated May 12th, 2021 13:38)
Roche’s Gazyvaro (obinutuzumab) has its Likelihood of Approval (LoA) jumping by 10 points in hairy cell leukaemia (HCL) on the heels of the investigator-led Phase I/II basket trial’s recruitment completion update on 29 April.
This LoA change is in combination with Phase I/II data showing obinutuzumab, plus Gilead Sciences’ entospletinib, is effective and well-tolerated in refractory or recurrent CLL. Credits: Medtech THAI STUDIO LAB 249/Shutterstock.com.
Share Article
Roche’s Gazyvaro (obinutuzumab) has its Likelihood of Approval (LoA) jumping by 10 points in hairy cell leukaemia (HCL) on the heels of the investigator-led Phase I/II basket trial’s recruitment completion update on 29 April. This LoA change is in combination with Phase I/II data showing obinutuzumab, plus Gilead Sciences’ entospletinib, is effecti